Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H25N3O2 |
| Molecular Weight | 243.3458 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)[C@H](N)C(=O)NCCN1CCOCC1
InChI
InChIKey=YNMUTYLWSRFTPX-QWRGUYRKSA-N
InChI=1S/C12H25N3O2/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15/h10-11H,3-9,13H2,1-2H3,(H,14,16)/t10-,11-/m0/s1
| Molecular Formula | C12H25N3O2 |
| Molecular Weight | 243.3458 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16707781 | http://adisinsight.springer.com/drugs/800045275
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16707781 | http://adisinsight.springer.com/drugs/800045275
LM11A-31 is a small, nonpeptide, monomeric ligand of p75 neutrophin receptor (p75NTR). The compound promotes neuron survival in vitro. PharmatrophiX is developing a modified version of LM11A-31 (LM11A 31 BHS) for the oral treatment of Alzheimer's disease.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P08138 Gene ID: 4804.0 Gene Symbol: NGFR Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL4762 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway. | 2016-12-06 |
|
| The Neurotrophic Factor Receptor p75 in the Rat Dorsolateral Striatum Drives Excessive Alcohol Drinking. | 2016-09-28 |
|
| Novel p75 neurotrophin receptor ligand stabilizes neuronal calcium, preserves mitochondrial movement and protects against HIV associated neuropathogenesis. | 2016-01 |
|
| Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75 NTR. | 2014-12 |
|
| Acute administration of the small-molecule p75(NTR) ligand does not prevent hippocampal neuron loss or development of spontaneous seizures after pilocarpine-induced status epilepticus. | 2014-10 |
|
| A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. | 2014 |
|
| Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice. | 2014 |
|
| A small molecule p75(NTR) ligand protects neurogenesis after traumatic brain injury. | 2013-11 |
|
| Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. | 2013-08 |
|
| Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. | 2013-01-09 |
|
| Suppression of immunodeficiency virus-associated neural damage by the p75 neurotrophin receptor ligand, LM11A-31, in an in vitro feline model. | 2012-06 |
|
| Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. | 2006-05-17 |
Patents
Sample Use Guides
In July 2016, Pharmatrophix initiated a phase IIa study to evaluate the safety, tolerability and exploratory endpoints of either placebo or two different oral doses of LM11A 31 BHS in patients with mild to moderate probable Alzheimer's disease (EudraCT2015-005263-16) . The 6 month trial which intends to enrol approximately 120 adult and elderly patients will assess safety and tolerability of 200mg and 400mg bid doses of LM11A 31 BHS (free base) administered for a period of 26 weeks in comparison to placebo. The study has been initiated in Austria and is expected to expand in other EU countries and in the US
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 17:11:12 GMT 2025
by
admin
on
Wed Apr 02 17:11:12 GMT 2025
|
| Record UNII |
Y9GUF3B7Q7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
102562-74-3
Created by
admin on Wed Apr 02 17:11:12 GMT 2025 , Edited by admin on Wed Apr 02 17:11:12 GMT 2025
|
PRIMARY | |||
|
Y9GUF3B7Q7
Created by
admin on Wed Apr 02 17:11:12 GMT 2025 , Edited by admin on Wed Apr 02 17:11:12 GMT 2025
|
PRIMARY | |||
|
18604758
Created by
admin on Wed Apr 02 17:11:12 GMT 2025 , Edited by admin on Wed Apr 02 17:11:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->LIGAND |
Blocks amyloid binding and protects cells.
|
||
|
ENANTIOMER -> ENANTIOMER |
|
||
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
